Last $1.16 USD
Change Today +0.04 / 3.57%
Volume 1.5K
PBSV On Other Exchanges
Symbol
Exchange
OTC US
As of 2:44 PM 11/24/14 All times are local (Market data is delayed by at least 15 minutes).

pharma-bio serv inc (PBSV) Snapshot

Open
$1.16
Previous Close
$1.12
Day High
$1.16
Day Low
$1.16
52 Week High
11/25/13 - $2.20
52 Week Low
06/25/14 - $0.80
Market Cap
26.7M
Average Volume 10 Days
10.6K
EPS TTM
$0.12
Shares Outstanding
23.0M
EX-Date
--
P/E TM
10.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for PHARMA-BIO SERV INC (PBSV)

Related News

No related news articles were found.

pharma-bio serv inc (PBSV) Related Businessweek News

No Related Businessweek News Found

pharma-bio serv inc (PBSV) Details

Pharma-Bio Serv, Inc. provides technical compliance consulting service, and microbiological and chemical laboratory testing services primarily to the pharmaceutical, chemical, medical device, and biotechnology industries. Its technical consulting services include regulatory compliance, validation, technology transfer, engineering, project management, and process support. The company also offers information technology services, such as Web pages and portals development, digital art design, intranets, extranets, software development that comprises database integration, Windows and Web applications development, software technical training and learning management systems, technology project management, and compliance consulting services. In addition, it provides microbiological testing services and chemical testing services; and technical trainings/seminars. Pharma-Bio Serv, Inc. markets its services through industry trade shows, professional conventions, industry publications, and company provided seminars in the United States, Puerto Rico, and Europe. The company was formerly known as Lawrence Consulting Group, Inc. and changed its name to Pharma-Bio Serv, Inc. in February 2006. Pharma-Bio Serv, Inc. was founded in 1993 and is headquartered in Dorado, Puerto Rico.

220 Employees
Last Reported Date: 01/29/14
Founded in 1993

pharma-bio serv inc (PBSV) Top Compensated Officers

Founder, Chairman, Principal Executive Office...
Total Annual Compensation: $105.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $195.3K
Chief Operating Officer and Secretary
Total Annual Compensation: $327.5K
Compensation as of Fiscal Year 2013.

pharma-bio serv inc (PBSV) Key Developments

Pharma-Bio Serv, Inc. Announces Resignation of Nelida Plaza as Chief Operating Officer and Secretary, Effective November 28, 2014

On November 11, 2014, Pharma-Bio Serv, Inc. accepted the resignation of Nelida Plaza as Chief Operating Officer and Secretary of the Company, effective November 28, 2014, for personal reasons. Ms. Plaza also resigned from other positions she held with the company's subsidiaries.

Pharma-Bio Serv, Inc. Reports Consolidated and Company Earnings Results for the Third Quarter and Nine Months Ended July 31, 2014

Pharma-Bio Serv, Inc. reported consolidated and company earnings results for the third quarter and nine months ended July 31, 2014. For the quarter, the company reported net revenues were $6.8 million a decrease of approximately $1.5 million when compared to the same periods last year. This decrease is mainly attributable to a decline in revenues from projects in the United States, Europe and Puerto Rico consulting markets and the Lab for $0.9, $0.4, $0.1 and $0.2 million, respectively, for the three-month period ended July 31, 2014. Net income was approximately $0.6 million a decrease of $0.6 million respectively, when compared with the same periods last year. For the nine months months, the company reported net revenues were $20.4 a decrease of approximately $3.9 million when compared to the same periods last year. This decrease is mainly attributable to a decline in revenues from projects in the United States, Europe and Puerto Rico consulting markets and the Lab for $2.2, $0.9, $0.4 and $0.3 million, respectively, for the nine-month period ended July 31, 2014. Net income was approximately $1.6 million a decrease of $2.1 million, respectively, when compared with the same periods last year. The net income variance, when compared to the same periods last year, is mainly attributable to the decline in revenue, the increase in selling general and administrative expenses for the business and operations investments incurred aimed to diversify markets, services and customer base, and the effect of the effective income tax rates (including Puerto Rico favorable tax grants) over income before tax.

Pharma-Bio Serv, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2014

Pharma-Bio Serv, Inc. reported earnings results for the second quarter and six months ended April 30, 2014. For the quarter, the company reported net revenues of $6.6 decrease of approximately $1.7 or 20.3% when compared to the same periods last year. This decrease is mainly attributable to a decline in revenues from projects in the United States, Europe and Puerto Rico consulting markets of $0.8, $0.4 and $0.3 million, respectively, for the three-month period ended April 30, 2014. Net income was approximately $0.3 million, a decrease of $1.1 million when compared with the same periods last year. The net income variance, when compared to the same periods last year, is mainly attributable to the decline in revenue, the increase in selling general and administrative expenses for the business and operations investments incurred aimed to diversify and expand markets and customer base, and the effect of the effective income tax rates (including Puerto Rico favorable tax grants) over income before tax. For the six months, the company reported net revenues of $13.6 million, a decrease of approximately $2.3 million or 14.6% when compared to the same periods last year. This decrease is mainly attributable to a decline in revenues from projects in the United States, Europe and Puerto Rico consulting markets of $1.3, $0.6 and $0.3 million, respectively, for the six-month period ended April 30, 2014. Net income was approximately $1.0 million, a decrease of $1.5 million when compared with the same periods last year. The net income variance, when compared to the same periods last year, is mainly attributable to the decline in revenue, the increase in selling general and administrative expenses for the business and operations investments incurred aimed to diversify and expand markets and customer base, and the effect of the effective income tax rates (including Puerto Rico favorable tax grants) over income before tax.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PBSV:US $1.16 USD +0.04

PBSV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PBSV.
View Industry Companies
 

Industry Analysis

PBSV

Industry Average

Valuation PBSV Industry Range
Price/Earnings 9.4x
Price/Sales 0.9x
Price/Book 1.3x
Price/Cash Flow 9.2x
TEV/Sales 0.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMA-BIO SERV INC, please visit www.pharmabioserv.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.